Toremifene in Treating Patients With Ovarian Cancer
Status:
Withdrawn
Trial end date:
2017-02-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using
toremifene may fight ovarian cancer by reducing the production of estrogen.
PURPOSE: Randomized phase II trial to study the effectiveness of toremifene in treating
patients who have recurrent or refractory ovarian cancer.